Современные критерии диагностики AL-амилоидоза
DOI: https://doi.org/10.29296/25877305-2022-07-17
Номер журнала:
7
Год издания:
2022
AL-амилоидоз (АL-A) – крайне гетерогенное по клиническим проявлениям заболевание с отсутствием патогномоничных симптомов. Ранняя диагностика и циторедуктивная терапия в большинстве случаев позволяют достигнуть положительного эффекта и остановить прогрессирование органной дисфункции. Приводится литературный обзор научной информации
о современных методах диагностики системного АL-A. Обращается внимание на трудности в диагностике, а также на основные клинические признаки, позволяющие заподозрить данное заболевание. Рассматриваются международные критерии, подтверждающие диагноз, и распространенность процесса, а также прогностические системы стадирования. Своевременная диагностика АL-A – важнейшая задача для врачей различных специальностей, которые на первых этапах встречаются с данными пациентами.
Ключевые слова:
AL-амилоидоз
диагностика
Для цитирования
Рехтина И.Г., Менделеева Л.П. Современные критерии
диагностики AL-амилоидоза
. Врач, 2022; (7): 82-86 https://doi.org/10.29296/25877305-2022-07-17Список литературы:
- Хышова В.А., Рехтина И.Г., Фирсова М.В. и др. Трудности в диагностике первичного AL-амилоидоза. Онкогематология. 2021; 16 (3): 74–82. DOI: 10.17650/1818‑8346‑2021‑16‑3‑74‑82 [Khyshova V.A., Rekhtina I.G., Firsova M.V. et al. Difficulties in diagnosis of primary AL-amyloidosis. Oncohematology. 2021; 16 (3): 74–82 (in Russ.)]. DOI: 10.17650/1818-8346-2021-16-3-74-82
- Lousada I., Comenzo R.L., Landau H. et al. Light chain amyloidosis: patient experience survey from the amyloidosis research consortium. Adv Ther. 2015; 32 (10): 920–8. DOI: 10.1007/s12325-015-0250-0.
- Palladini G. et al. Systemic Light Chain Amyloidosis across Europe: Key Outcomes from a Retrospective Study of 4500 Patients. Blood (S1.). 2020; S1: Abstract 136.
- Gertz M.A., Comenzo R, Falk R. H. et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Am J Hematol. 2005; 79 (4): 319–28. DOI: 10.1002/ajh.20381
- Merlini G., Dispenzieri A., Sanchorawala V. et al. Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers. 2018; 4 (1): 38. DOI: 10.1038/s41572-018-0034-3
- Hallek R.M., Lehmacher K.W., Marx K.N. et al. Klinische studien langzeit-follow-up monoklonaler gammopathien unklarer signifikanz (MGUS). Der Internist. 2018; 59: 639–40.
- Quock T.P., Yan T., Chang E. et al. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018; 2 (10): 1046–53. DOI: 10.1182/bloodadvances.2018016402
- Rahel S., Flammer A.J., Sabine G. et al. Expert recommendation from the swiss amyloidosis network (SAN) for systemic AL-amyloidosis. Swiss Med Wkly. 2020; 150: w20364. DOI: 10.4414/smw.2020.20364
- Quarta C.C., Gonzalez-Lopez E., Gilbertson JA. et al. Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur Heart J. 2017; 38 (24): 1905–8. DOI: 10.1093/eurheartj/ehx047
- Kimmich C., Schönland S., Kräker S. et al. Amyloid in bone marrow smears in systemic light-chain amyloidosis. Amyloid. 2017; 24 (1): 52–9. DOI: 10.1080/13506129.2017.1314959
- Muchtar E., Dispenzieri A., Lacy M.Q. et al. Overuse of organ biopsies in immunoglobulin light chain amyloidosis (AL): the consequence of failure of early recognition. Ann Med. 2017; 49 (7): 545–51. DOI: 10.1080/07853890.2017.1304649
- Systemic Light chain amyloidosis. NCCN Clinical Practical Gaidenlines in Oncology. Version 1, 2022. URL: https://www.nccn.org/professionals/physician_gls/pdf/amyloidosis.pdf
- Kyle R.A., Therneau T.M., Rajkumar S.V. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med. 2006; 354 (13): 1362–9. DOI: 10.1056/NEJMoa1709974
- Phull P, Sanchorawala V, Connors L.H. et al. Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). Amyloid. 2018; 25 (1): 62–7. DOI: 10.1080/13506129.2018.1436048
- Palladini G., Milani P., Merlini G. Management of AL Amyloidosis in 2020. Blood. 2020; 136 (23): 2620–7. DOI: 10.1182/blood.2020006913
- Fotiou D., Dimopoulos M.A., Kastritis E. Systemic AL Amyloidosis: сurrent аpproaches to diagnosis and management. Hemasphere. 2020; 4 (4): e454. DOI: 10.1097/HS9.0000000000000454
- Phelan D., Collier P., Thavendiranathan P. Relative apical sparing of longitudinal strain using two-dimensional speckle-tracking echocardiography is both sensitive and specific for the diagnosis of cardiac amyloidosis. Heart. 2012; 98 (19): 1442–8. DOI: 10.1136/heartjnl-2012-302353
- Salinaro F., Meier-Ewert H.K., Miller E.J. Longitudinal systolic strain, cardiac function improvement, and survival following treatment of light-chain (AL) cardiac amyloidosis. Eur Heart J Cardiovasc Imaging. 2017; 18 (9): 1057–64. DOI: 10.1093/ehjci/jew298
- Fontana M., Pica S., Reant P. et al. Prognostic value of late gadolinium enhancement cardiovascular magnetic resonance in cardiac amyloidosis. Circulation. 2015; 132 (16): 1570–9. DOI: 10.1161/CIRCULATIONAHA.115.016567
- Banypersad S.M., Sado D.M., Flett A.S. et al. Quantification of myocardial extracellular volume fraction in systemic AL amyloidosis: An equilibrium contrast cardiovascular magnetic resonance study. Circ Cardiovasc Imaging. 2013; 6 (1): 34–9. DOI: 10.1161/CIRCIMAGING.112.978627
- Dispenzieri A., Kyle R., Merlini G. et al. International myeloma working group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia. 2009; 23: 215–24. DOI: 10.1038/leu.2008.307
- Bochtler T., Hegenbart U., Kunz C. et al. Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J Clin Oncol. 2015; 33: 1371–8. DOI: 10.1200/JCO.2014.57.4947
- Bochtler T., Hegenbart U., Kunz C. et al. Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone. Amyloid. 2014; 21: 9–17. DOI: 10.3109/13506129.2013.854766
- Muchtar E., Dispenzieri A., Kumar S.K. et al. Interphase fluorescence in situ hybridization in untreated AL amyloidosis has an independent prognostic impact by abnormality type and treatment category. Leukemia. 2017; 31: 1562–9. DOI: 10.1038/leu.2016.369
- Sidana S., Larson D.P., Greipp P.T. et al. IgM AL amyloidosis: delineating disease biology and outcomes with clinical, genomic and bone marrow morphological features. Leukemia. 2020; 34 (5): 1373–82. DOI: 10.1038/s41375-019-0667-6
- Dispenzieri A., Gertz M.A., Kyle R.A. et al. Serum cardiac troponins and N-terminal pro-brain natriuretic peptide: a staging system for primary systemic amyloidosis. J Clin Oncol. 2004; 22: 3751–7. DOI: 10.1200/JCO.2004.03.029
- Wechalekar A.D., Schonland S.O., Kastritis E. et al. A European collaborative study of treatment outcomes in 346 patients with cardiac stage III AL amyloidosis. Blood. 2013; 121: 3420–34. DOI: 10.1182/blood-2012-12-473066
- Kumar S., Dispenzieri A., Lacy M.Q. et al. Revised prognostic staging system for light chain amyloidosis incorporating cardiac biomarkers and serum free light chain measurements. J Clin Oncol. 2012; 30 (9): 989–95. DOI: 10.1200/JCO.2011.38.5724
- Palladini G., Hegenbart U., Milani P. A staging system for renal outcome and early markers of renal response to chemotherapy in AL amyloidosis. Blood. 2014; 124 (15): 2325–32. DOI: 10.1182/blood-2014-04-570010